LONDON, Nov 16- GlaxoSmithKline Plc's new breast cancer pill Tykerb will receive a priority review from U.S. regulators in a move that should speed its path onto the world's biggest drugs market next year, it said on Thursday.
GSK.L closed trading thursday at $51.97 or up 42 cents.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment